Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.

Literature DB >> 33456757

Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.

Eleftheria Tampouratzi¹, Theodora Kanni², John Katsantonis¹, Theodora Douvali².

Abstract

Hidradenitis suppurativa and psoriasis are considered chronic inflammatory diseases suggesting the existence of common pathogenetic pathways. We present two cases of comorbid psoriasis and hidradenitis suppurativa, treated with certolizumab pegol and brodalumab due to failure of response to other conventional therapies. Monoclonal antibody therapies have revolutionized the treatment of chronic inflammatory disorders such as psoriasis and hidradenitis suppurativa. Given the good clinical response to anti-IL-17 and anti-tumor necrosis factor agents in patients undergoing psoriasis and hidradenitis treatment, investigations on this direction could represent the starting point in new therapeutic approach for revolutionary treatment in these difficult-to-treat diseases. Copyright:

Entities: Chemical Disease Gene Species

Keywords: brodalumab; certolizumab; hidradenitis suppurativa; psoriasis

Year: 2019 PMID： 33456757 PMCID： PMC7791350 DOI： 10.12688/f1000research.21216.2

Source DB: PubMed Journal: F1000Res ISSN： 2046-1402

14 in total

1. Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center.

Authors: Mital Patel; Jeffrey M Cohen; Natalie A Wright; Joseph F Merola; Abrar A Qureshi; Ruth Ann Vleugels
Journal: J Am Acad Dermatol Date: 2015-10 Impact factor: 11.527

2. Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study.

Authors: Khalaf Kridin; Michal Shani; Yochai Schonmann; Shani Fisher; Guy Shalom; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal: J Am Acad Dermatol Date: 2018-11-28 Impact factor: 11.527

3. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.

Authors: Grace Kimmel; Margot Chima; Hee Jin Kim; Jennifer Bares; Christopher J Yao; Giselle Singer; Soo Jung Kim; Jerry Bagel; Mark Lebwohl
Journal: J Am Acad Dermatol Date: 2019-05-10 Impact factor: 11.527

Review 4. Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions.

Authors: Huidi Tchero; Christian Herlin; Farid Bekara; Sergiu Fluieraru; Luc Teot
Journal: Indian J Dermatol Venereol Leprol Date: 2019 May-Jun Impact factor: 2.545

5. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.

Authors: Charlene Porter; Sylvia Armstrong-Fisher; Tim Kopotsha; Bryan Smith; Terry Baker; Lara Kevorkian; Andrew Nesbitt
Journal: J Reprod Immunol Date: 2016-04-14 Impact factor: 4.054

Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.

1. Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center.

2. Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study.

3. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.

Review 4. Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions.

5. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer.

Review 6. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

7. Compartmentalized Cytokine Responses in Hidradenitis Suppurativa.

8. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.

9. A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab.

10. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa.